



Requested
7/1/2005

FACSIMILE

PLEASE CALL US AT (703) 413-3000 IF THE MESSAGE YOU RECEIVE IS INCOMPLETE OR NOT LEGIBLE

ATTORNEYS AT LAW

1940 DUKE STREET
ALEXANDRIA, VIRGINIA 22314
USA

(703) 413-3000
(703) 413-2220 FACSIMILE

OBLONPAT@OBLON.COM

PATENT, TRADEMARK AND COPYRIGHT LAW
AND RELATED FEDERAL AND ITC LITIGATION

WWW.OBLON.COM

TO NAME <u>Examiner Lorraine Spector</u> <u>USPTO-GAU 1647</u> COMPANY/FIRM NUMBER OF PAGES INCLUDING COVER: <u>9</u>	DATE <u>July 1, 2005</u> <u>571-273-0893</u> FAX # CONFIRM FAX: <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO
FROM NAME <u>Charles L. Gholz</u> <u>703-412-6485</u> DIRECT PHONE #	<u>268513US</u> OUR REFERENCE <u>SN 09/709,045</u> YOUR REFERENCE

MESSAGE

Amendment Under CFR 1.116 Expedited Prosecution

Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error or are not sure whether it is privileged, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service at our Expense. Thank You.

DOCKET NO:

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
M. RIGDON LENTZ : EXAMINER: L. SPECTOR
SERIAL NO: 09/709,045 :
FILED: NOVEMBER 10, 2000 : GROUP ART UNIT: 1647
FOR: METHOD AND SYSTEM TO :
REMOVE CYTOKINE INHIBITOR IN
PATIENTS

AMENDMENT UNDER C.F.R. 1.116
EXPEDITED PROSECUTION

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Office Action dated January 6, 2005, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.